From Maternal Intensive Care Unit Sedation to Offspring Neurodevelopment: An Integrated Placental-Transfer and Critical-Care Evidence Synthesis – A Systematic Review
Wiku Andonotopo, Muhammad Adrianes Bachnas, Wisnu Prabowo, Eric Edwin Yuliantara, Mochammad Besari Adi Pramono, Julian Dewantiningrum, Efendi Lukas, I Nyoman Hariyasa Sanjaya, Anak Agung Gede Putra Wiradnyana, Anak Agung Ngurah Jaya Kusuma, Khanisyah Erza Gumilar, Ernawati Darmawan, Muhammad Ilham Aldika Akbar, Dudy Aldiansyah, Aloysius Suryawan, Ridwan Abdullah Putra, Theresia Monica Rahardjo, Anita Deborah Anwar, Cut Meurah Yeni, Nuswil Bernolian, Laksmana Adi Krista Nugraha, Waskita Ekamaheswara Kasumba Andanaputra, Wibisana Andika Krista Dharma, Milan StanojevicAbstract
Sedation and analgesia are often unavoidable in critically ill pregnant and postpartum patients, yet their downstream implications for fetal and offspring neurodevelopment remain poorly conceptualized. In clinical practice, decisions are frequently driven by urgency rather than evidence, while the literature addressing these exposures is fragmented across critical care medicine, anesthesiology, placental pharmacology, and developmental neuroscience. We conducted a systematic review to integrate these disparate domains and to examine how maternal intensive care unit (ICU) sedation intersects with placental drug transfer and neurodevelopmental vulnerability. Following PRISMA 2020 guidance, we searched electronic databases and trial registers, identifying 1326 records, of which 32 studies met inclusion criteria after screening and eligibility assessment. Included studies spanned observational cohorts, mechanistic and translational investigations, pharmacokinetic modeling, and experimental animal work. Rather than demonstrating consistent drug-specific neurotoxicity, the evidence suggested probabilistic neurodevelopmental trajectories shaped by exposure duration, cumulative dosing, gestational timing, placental transport, and metabolism, in the physiologic context of maternal critical illness. Importantly, the placenta emerged not as a passive conduit but as an active modulator whose regulatory capacity changes across gestation, complicating simplistic risk attribution. Across studies, long-term offspring follow-up was limited, heterogeneous, and frequently absent, constraining causal inference. Synthesizing these findings, we propose that fetal and offspring risk cannot be inferred from sedative class alone and that timing and maternal illness severity are central modifiers of effect. This review highlights the need for gestation-aware pharmacokinetic models, structured neurodevelopmental surveillance, and ethically grounded inclusion of pregnant patients in ICU research, shifting the field from avoidance-based caution toward context-informed clinical reasoning.